Maxim Group analyst Jason McCarthy has maintained their bullish stance on DARE stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Daré Bioscience’s promising outlook. The company is set to launch its topical Sildenafil Cream in December through the 503B compounding pathway, which is expected to generate near-term revenue. This launch is part of a broader strategy to expand their product pipeline, including the DARE-HRT1 and other innovative treatments.
Additionally, Daré is making significant progress in its clinical programs, such as the ongoing Ovaprene P3 study, which shows promising results with a pregnancy rate comparable to or better than existing contraceptive methods. The company’s financial position is bolstered by recent funding, ensuring operations into the second half of 2026. Furthermore, the support from non-dilutive grants for pipeline development and the upcoming clinical studies for products like DARE-HPV and DARE-LARC1 contribute to a positive long-term growth trajectory, justifying the Buy rating.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
DARE’s price has also changed moderately for the past six months – from $2.890 to $1.860, which is a -35.64% drop .